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Nucleic acid-binding innate immune receptors
such as Toll-like receptor 7 (TLR7) and TLR9
have been implicated in the development of
some autoimmune pathologies. The Y chromo-
some-linked genomic modifier Yaa, which cor-
relates with a duplication of Tlr7 and 16 other
genes, exacerbates lupus-like syndromes in
several mouse strains. Here we demonstrated
that duplication of the Tlr7 gene was the sole
requirement for this accelerated autoimmunity,
because reduction of Tlr7 gene dosage abol-
ished the Yaa phenotype. Further, we described
new transgenic lines that overexpressed TLR7
alone and found that spontaneous autoimmu-
nity developed beyond a 2-fold increase in
TLR7 expression. Whereas a modest increase
in Tlr7 gene dosage promoted autoreactive
lymphocytes with RNA specificities and mye-
loid cell proliferation, a substantial increase in
TLR7 expression caused fatal acute inflamma-
tory pathology and profound dendritic cell dys-
regulation. These results underscore the impor-
tance of tightly regulating expression of TLR7
to prevent spontaneous triggering of harmful
autoreactive and inflammatory responses.
INTRODUCTION
Innate immune responses initiated by Toll-like receptors
(TLRs) are a critical first line of defense against pathogens
and also serve to enhance adaptive responses (Kawai and
Akira, 2007). In pathological conditions, however, innate
responses can exacerbate autoimmune conditions and
trigger harmful inflammatory pathologies. Engagement
of TLRs in dendritic cells (DCs) induces the production
of inflammatory cytokines such as IL-6, TNF-a, and typeImI interferons (Bekeredjian-Ding et al., 2005; Honda et al.,
2005; Hornung et al., 2005; Lund et al., 2004; Pascual
et al., 2006; Savarese et al., 2006; Vollmer et al., 2005).
TLRs in B cells act in synergy with the antigen receptor
to induce proliferation, isotype switching, and plasma
cell differentiation (Berland et al., 2006; Lartigue et al.,
2006; Lau et al., 2005; Leadbetter et al., 2002; Pasare
and Medzhitov, 2005; Savarese et al., 2006; Viglianti
et al., 2003). Thus, tight regulation of TLR-induced re-
sponses is necessary to maintain a healthy and tolerant
immune environment.
The role of TLRs in the onset of autoimmune pathologies
has been effectively addressed in the context of murine
models of systemic lupus erythematosus (SLE). In a num-
ber of these models of lupus, it has been shown that in-
hibitory and proapoptotic receptors such as FcgRIIB,
Fas, and SLAM family members regulate lymphocyte acti-
vation and prevent the expansion of self-reactive B cells
(Bolland and Ravetch, 2000; Wandstrat et al., 2004; Wata-
nabe-Fukunaga et al., 1992). Both in lupus patients and in
mousemodels of lupus, systemic autoimmunity is directed
againstmultiple self-antigens that commonly includeDNA,
histones, RNA, and ribonucleoproteins (D’Cruz, 2006). A
synergistic effect between nucleic acid-binding TLRs and
the antigen receptor of self-reactive B cells has been pro-
posed to explain the preference for nuclear specificities in
autoantibodies (Christensen and Shlomchik, 2007; Deane
and Bolland, 2006; Marshak-Rothstein and Rifkin, 2007).
With regard to RNA-related specificities, B cell receptor
transgenic models have been used to show that TLR7,
which recognizes single-stranded RNA (ssRNA) of viral or-
igin, mediates activation of RNA-specific B cells (Barrat
et al., 2005; Berland et al., 2006; Savarese et al., 2006). De-
letion of the Tlr7 gene was shown to be protective in the
MRL/lpr lupus mouse model and to reduce the amount of
antibodies against RNA-related antigens (Christensen
et al., 2006).
Mice bearing the Yaa locus provide a prime example of
how important it is to control the expression of innate
receptors. In Yaa mice, a hyperactive phenotype in B
and dendritic cells was found to correlate with a genomicmunity 27, 801–810, November 2007 ª2007 Elsevier Inc. 801
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Augmented TLR7 Expression Promotes AutoimmunityFigure 1. Increased Tlr7 Gene Dosage Is Necessary for Hyperresponsiveness in the Yaa Strain
(A) Spleens from Tlr7+/Y, Tlr7/Y, Tlr7+/Yaa, and Tlr7/Yaa mice were analyzed for the marginal zone B cell compartment with CD21 and CD23 shown by
the gate and the percents of cells. Data are representative of four independent experiments.
(B) Histological assessment of the marginal zone B cell population in spleens from Tlr7+/Y, Tlr7/Y, Tlr7+/Yaa, and Tlr7/Yaa mice, with antibodies to
marginal zone macrophages (anti-MOMA1, shown in green) and B cells (anti-B220, shown in red). Data are representative of four independent
experiments.
(C) Proliferation assay of splenocytes in response to Imiquimod and CpG by 3H-thymidine incorporation. Shown is the mean ± SD. Data are repre-
sentative of four independent experiments with mice aged 2–3 months.translocation of at least 17 genes X-chromosomal onto the
pseudoautosomal region of the Y chromosome, one being
Tlr7 (Pisitkun et al., 2006; Subramanian et al., 2006). The
Yaa locus, which stands for Y chromosome-linked auto-
immune accelerator, produces a striking acceleration of
autoimmunity when bred to other models of lupus such
as the FcgRIIB-deficient mouse (Amano et al., 2003; Bol-
land et al., 2002). In a healthy genetic background, such as
the C57BL/6 strain, addition of the Yaa locus diminishes
the marginal zone B cell population in the spleen and in-
duces a moderate myeloid cell expansion. Although initial
reports about this genomic duplication focused on hyper-
responsiveness to TLR7 ligands in this strain, the nature of
how this allele accelerates systemic autoimmunity re-
mains unclear because of the fact that multiple genes
are duplicated. For example, Tlr7 could function with
one or more of the other duplicated genes to potentiate
the acceleration in pathology, or the increase in TLR7802 Immunity 27, 801–810, November 2007 ª2007 Elsevier Incexpression may be merely correlative with the develop-
ment of autoimmunity. Thus, the precise importance of
Tlr7 gene duplication in the Yaa mouse remains undeter-
mined (Marshak-Rothstein and Rifkin, 2007). In this study,
we used two approaches to answer this question, by
either decreasing or increasing Tlr7 gene dosage. When
we lowered Tlr7 gene dosage, we were able to ablate
the hyperresponsiveness caused by the Yaa allele, and
when bred to FcgRIIB-deficient mice, we were able to
eliminate the nucleolar antibody response, enhancement
in pathology, and mortality that is seen in the Yaa mouse.
In contrast, increasing Tlr7 gene dosage via the generation
of TLR7 transgenic mice resulted in the development of
acute systemic autoimmune disease characterized by
RNA autoantibody production, glomerulonephritis, DC
expansion, anemia, and a proinflammatory interferon sig-
nature in the DCs. The combination of these two tech-
niques allows us to conclude that Tlr7 gene dosage is.
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Augmented TLR7 Expression Promotes AutoimmunityFigure 2. Increased Tlr7 Gene Dosage Is Necessary for the Accelerated Pathology in the Yaa Mouse
(A) Mortality curves of R2 Tlr7+/Yaa (blue) and R2 Tlr7/Yaa (red) mice, where n = 5 in each group.
(B) Top row indicates anti-nuclear antibody (ANA) tests detect nucleolar antibodies in stains with serum from 5-month-old R2 Tlr7+/Yaa mice (left) and
homogeneous nuclear pattern in stains with serum from R2 Tlr7/Yaa mice (right). Bottom row indicates histological analysis of glomeruli from
5-month-old R2 Tlr7+/Yaa (left) and R2 Tlr7/Yaa (right) kidneys stained with hematoxylin and eosin. Data are representative of at least four independent
experiments.
(C) RNA-specific antibodies were quantitated in sera from B6, R2 Tlr7+/Yaa, and R2 Tlr7/Yaa, and R2 mice aged 4–6 months. Data are shown in terms
of units, based on control serum provided by the ELISAmanufacturer. Data are shown as mean ± SD (n = 6), except for the R2 sera, which is from one
experiment.both necessary and sufficient to promote autoantibody
production and pathological disease associated with lupus.
RESULTS
Increased Tlr7 Gene Dosage Is Necessary
for the Yaa Phenotype
To determine whether Tlr7 is the critical gene for the Yaa
phenotype, we bred B6.Yaa males to Tlr7/ female
mice so that the two copies of the Tlr7 gene were reduced
to one copy as in wild-type male mice. Because of its lo-
cation on the X chromosome, the Tlr7-deficient allele elim-
inates X-chromosomal expression of TLR7 while main-
taining TLR7 expression on the Yaa Y chromosome.
Thus, we will refer to wild-typemalemice as Tlr7+/Y, TLR7-
deficient males as Tlr7/Y, and Yaa males as Tlr7+/Yaa,
whereas the combination of Yaa and the Tlr7-deficient
allele on the X chromosome produces Tlr7/Yaa mice. Al-
though the marginal zone (MZ) B cell compartment was
markedly reduced in the spleen of Tlr7+/Yaa mice as previ-
ously reported (Amano et al., 2003), we observed wild-
type numbers of MZ B cells in Tlr7/Yaa mice, and even
slightly increased numbers in Tlr7/Y mice (Figures 1A
and 1B). The hyperresponsiveness to the TLR7 ligand imi-
quimod seen in the Yaa strain was also reduced to wild-
type numbers in Tlr7/Yaa splenocytes; no proliferation
was observed in Tlr7/Y mice in these conditions
(Figure 1C). To examine the consequences of lowered
Tlr7 gene dosage on the development of a lupus-like syn-
drome, we bred the Fcgr2b/Yaa males (hereafter re-
ferred to as R2 Tlr7+/Yaa) to female mice bearing the Tlr7-
deficient allele. Previous studies showed that addition of
the Yaa allele to Fcgr2b/ mice shifts their autoantibody
pattern from a homogenous nuclear to a nucleolar pattern
and that mortality is markedly accelerated (Bolland et al.,
2002). We observed that reduction of Tlr7 gene-copy
number resulted in increased survival of these mice. R2
Tlr7+/Yaa mice became moribund at 5 months of age,Imand kidney disease was markedly decreased in the R2
Tlr7/Yaa littermates of the same age (Figures 2A and
2B). Additionally, splenomegaly was decreased in R2
Tlr7/Yaa littermates (data not shown). In contrast to the
nucleolar autoantibody pattern seen from R2 Tlr7+/Yaa
sera, immunofluorescence analysis of autoantibodies in
R2 Tlr7/Yaa mice showed a homogenous nuclear appear-
ance (Figure 2B). This change in autoantibody pattern cor-
related with a reduction of anti-RNA specificities in the se-
rum. RNA antibodies detected by ELISA were reduced in
R2 Tlr7/Yaa compared to those found in R2 Tlr+/Yaa sera.
This reduction resulted in concentrations similar to those
found in R2/ mice but slightly above the amounts of
wild-type mice (Figure 2C). Overall, R2 Tlr7/Yaa mice
died from a lupus-like syndrome at a later age and in lower
numbers than did R2 Tlr7+/Yaa mice. Cellular analysis com-
paring these mice showed reductions in activation in R2
Tlr7/Yaa splenocytes and reduced number of antibody-
producing cells, as compared to R2 Tlr7+/Yaa splenocytes
(Figure S1 in the Supplemental Data available online).
Thus, the increase in TLR7 expression is necessary for
the accelerated development of systemic autoimmunity
seen in the Yaa mouse.
Increased Tlr7 Dosage Is Sufficient
to Induce Systemic Autoimmunity
To examine whether TLR7 was sufficient to produce the
Yaa phenotype, we generated transgenic mice that over-
expressed TLR7 alone. Starting with the RP23-139P21
BAC construct that contains the Tlr7, Tlr8, and Tmsb4x
genes, we replaced the first 83 kb with a neomycin cas-
sette so that Tlr7 would be the only gene expressed
from this clone. The final construct contained approxi-
mately 40 kb both upstream and downstream of Tlr7,
because it was designed to maintain tissue-specific ex-
pression comparable to that of the endogenous gene
(Figure 3A). Microinjection of C57BL/6 zygotes with this
DNA produced six founder lines that had varying copymunity 27, 801–810, November 2007 ª2007 Elsevier Inc. 803
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Augmented TLR7 Expression Promotes AutoimmunityFigure 3. Construction and Characterization of BAC Transgenic Mice Overexpressing TLR7
(A) Layout of BAC clone RP23-139P21 and recombineering strategy for producing TLR7 transgenic lines. Primers used to excise sequences contain-
ing Tlr8 and Tmsb4x are indicated as triangles.
(B) Genomic DNA andmRNA levels in founder strains. Numbers were calculated by performing quantitative PCR and comparing TLR7 threshold cycle
values between B6 control littermates and Tg mice, with tail DNA or follicular B cell mRNA from young mice (<3 months). Data were obtained from at
least three mice per genotype.
(C) Spontaneousmortality in TLR7.Tg lines. Survival curves of B6 or TLR7.Tg strains were measured over the course of 10months. Data are based on
5 mice for Tg7.1 and Tg7.6 or 10 mice for all other strains.
(D) RNA-specific antibody production in TLR7.Tg strains. Quantification of units was performed as in Figure 2. Sera from at least four mice per strain
were used to detect RNA antibodies with an ELISA.
(E) Autoantibody production shown by ANA tests and glomerulonephritis shown by hematoxylin and eosin-stained kidney sections from TLR7.Tg
strains. Data are based on at least five mice per transgenic line and were obtained from mice that were 3–9 months old.number of Tlr7 at the genomic level, ranging from 4 to 32
copies of the gene. Expression at the mRNA level ranged
between 4- and 16-fold higher than the wild-type, as
judged by quantitative PCR on follicular B cell cDNA
(Figure 3B). Increased expression of TLR7 was also
detected to an even greater extent in purified DC mRNA,
whereas CD4+ T cells did not show similar patterns of
overexpression (data not shown). Although our initial
goal was to cross these animals with Fcgr2b/ animals,
we observed lethality to varying degrees in the various
TLR7 transgenic (hereafter TLR7.Tg) founder lines, which
correlated with the extent of TLR7 overexpression at the804 Immunity 27, 801–810, November 2007 ª2007 Elsevier IncmRNA level (Figure 3C). Additionally, in the five studied
strains, autoantibody production and glomerulonephritis
could be detected as the mice aged (Figures 3D and
3E), indicating that TLR7 overexpression results in an au-
toimmune syndrome. Further analysis of autoantibody
production in these mice showed that while ANA patterns
varied somewhat, wheremost sera appeared either mixed
cytoplasmic or nucleolar, an ELISA showed that all strains
analyzed were positive for anti-RNA IgG production
(Figure 3D). The penetrance and nature of the autoim-
mune pathology noted in the examined founder lines is
summarized in Table 1. Overall, the creation of mice.
Immunity
Augmented TLR7 Expression Promotes AutoimmunityTable 1. Autoantibody Profiles and Pathological Manifestations in TLR7.Tg Mice
Strain
ANA+ (Nuclear,







7.1 5 (1,0,4) / 7 6 / 6 3 / 6 6 / 6 5 / 6 0 / 6
7.2 5 (1,0,4) / 6 4 / 5 4 / 5 4 / 5 3 / 5 0 / 5
7.4 7 (0,1,6) / 7 6 / 6 5 / 6 6 / 6 5 / 6 0 / 6
7.5 7 (4,3,0) / 8 5 / 5 3 / 5 5 / 5 3 / 5 0 / 5
7.6 8 (1,3,4) / 9 8 / 8 6 / 8 8 / 8 3 / 8 2 / 8
a Spleen size > 300 mg.
bKidney histology shows a majority of glomeruli being increased in size and cellularity.
c >10% CD11c+ cells in blood.
d Presence of inflammatory cells in liver or lung.overexpressing TLR7 alone was able to produce an auto-
immune syndrome on its own.
Moderately Increased Tlr7 Gene Dosage
Recapitulates the Yaa Phenotype
We first tested the extent of TLR7-mediated activation in
splenocytes from TLR7.Tg mice with medium amounts
of overexpression (i.e., 4- to 8-fold overexpression) and
compared them to B6 littermates. FACS analysis of vari-
ous splenic cell compartments in TLR7.Tg.6 mice showed
that young (2- to 3-month-old) transgenic animals had
a marginal zone defect, similar to what was observed in
the Yaa mice (Figure 4A). Both B and T lymphocytes
from TLR7.Tg.6 mice showed spontaneous activation,
as indicated by the fact that CD69 expression was found
more frequently in TLR7.Tg.6 splenocytes (Figure 4B).
Furthermore, the CD11c+ population was expanded
substantially in young TLR7.Tg6 mice, similar to what
was found in previous studies on aging Yaa mice (Amano
et al., 2005). These data on cellular subsets in TLR7.Tg.6
mice are quantitated in Table S1. By using splenocytes
from the TLR7.Tg.6 line, we found increased responsive-
ness to the TLR7 ligand imiquimod when compared to
wild-type splenocytes (Figure 4C). Because we had de-
tected autoantibody production in serum from all the
TLR7.Tg.6 mice, we analyzed the B cells in these mice
and noted that the B220loCD138+ population, most likely
representing antibody-producing cells, was increased
(Figure 4D). A large number of immunoglobulin-loaded
cells was detected by immunohistochemistry of splenic
sections by kappa chain antibody staining (Figure 4E).
Thus, a 4- to 8-fold increase in expression of TLR7 pro-
duces a phenotype that resembles the Yaa phenotype
but is more severe, in that in TLR7.Tg.6 mice, dendritic
cells expand even at a young age, both B and T cells are
spontaneously activated, and antibody-producing B cells
are substantially increased.
High TLR7 Expression Induces Proliferation
of Inflammatory DCs and Anemia
We next characterized immune development in the two
TLR7.Tg strains that overexpressed TLR7 between
8- and 16-fold over wild-type littermates. In these studies,Iwe focused on the TLR7.Tg.1 line, though similar results
were found with TLR7.Tg.4 mice (data not shown). At
a young age (n < 8 weeks), the phenotype of TLR7.Tg.1
mice was quite similar to those in TLR7.Tg strains that
expressed lower amounts of TLR7, with increases in the
degree of the severity of the phenotype but general simi-
larities between all strains of mice (data not shown). How-
ever, as we allowed the strains to age beyond 2 months,
we noted high incidences of early lethality with high over-
expression of TLR7 (Figure 3C). Analysis of morbid ani-
mals showed severe splenomegaly (Table S2) that could
be identified as early as 2 months of age and resulted in
spleens weighing 30 times more than those of wild-type
littermates. Cellular and histological analysis of blood
and spleen showed a large proliferation of CD11c+ cells
(Figure 5A). Phenotypically, these CD11c+ cells expressed
other molecules such as CD11b, CD8, and B220 in com-
parable proportions to wild-type cells. TLR7.Tg.1 DCs
had increased expression of molecules that are indicative
of enhanced activation, such as class II MHC and CD80
(Figure 5B; Table S2). Highly elevated amounts of the
inflammatory cytokines TNF-a, IL-6, and MCP-1 were
detected in sera from TLR7.Tg.1mice (Figure 5C). Expres-
sion analysis of DC cDNA from TLR7.Tg.1 mice also
showed a significant increased in the expression of IRF5
and SOCS-1, which are two signaling molecules whose
upregulation is associated with inflammation mediated
through type I interferons (Figure 5D). A severe anemia
also accompanied these traits that included marked re-
ductions in red blood cells (RBCs) and severe deficiencies
in platelets (Figures 6A and 6B). Although sera from these
mice were negative for RBC antibodies as assessed by
direct and indirect Coombs’ assays (data not shown),
some sections did show what appeared to be erythropha-
gocytosis (Figure S2). In contrast, there were signs of
compensatory erythropoiesis, as Ter-119+ erythroblasts
were also expanded in spleens of anemic TLR7.Tg.1
mice (Figure 6C). This erythropoiesis was found to be
restricted to the periphery, as indicated by the fact that
bone marrow from TLR7.Tg.1 mice did not show similar
enhancements in erythroblasts (data not shown). Addi-
tionally, megakaryocyte development was not abnormal
in either the spleen or the bone marrow, suggesting thatmmunity 27, 801–810, November 2007 ª2007 Elsevier Inc. 805
Immunity
Augmented TLR7 Expression Promotes AutoimmunityFigure 4. TLR7 Transgenic Mice Recapitulate the Enhanced Responses Seen in the Yaa Strain and Promote Lymphocyte Activa-
tion
(A) Flow cytometric analysis of CD21 and CD23 expression shows marginal zone B cell development (left), and CD11c+ expression shows dendritic
cell development (right) in splenocytes from B6 (top) and TLR7.Tg.6 (bottom) mice. Numbers shown represent percentages. Data are representative
of four independent experiments.
(B) Spontaneous lymphocyte activation in B6 and TLR7.Tg.6 mice shown by FACS analysis with antibodies to CD69. B220+ gated cells are overlayed
in the top histogram, and CD4 gated cells are shown on the bottom, where numbers represent percent positive. Data are representative of four
independent experiments.
(C) Proliferation assay with 3H-thymidine incorporation in response to imiquimod or CpG in both B6 and TLR7.Tg.6 splenocytes. Data are shown as
mean ± SD of ccpm in triplicate wells and are representative of three independent experiments.
(D) Flow cytometric analysis of splenocytes from B6 (top) and TLR7.Tg.6 (bottom) mice shows the B220loCD138+ population. Data are representative
of three independent experiments.
(E) Histological analysis of spleen sections from B6 (top) and TLR7.Tg.6 (bottom) mice shows antibody-producing lymphocytes, as judged by
Ig-Kappa chain stains. Data are representative of three independent experiments and were obtained from mice that were 2–3 months of age.the decreases in RBCs and platelets were not due to
a decreased production of these cells (data not shown).
Histological analysis showed that as myeloid cells ex-
panded, there was a concomitant loss of lymphocytes,
as white pulp regions were severely atrophied in spleens
of dying TLR7.Tg.1 mice (Figure 6D). Thus, whereas in-
creased Tlr7 gene dosage produced an environment
that stimulated autoantibody-secreting B cells, higher
gene dosage resulted in a shift to a highly inflammatory
and lymphopenic environment as DCs expressing TLR7
expand in an uncontrolled fashion and promote anemia.806 Immunity 27, 801–810, November 2007 ª2007 Elsevier IncDISCUSSION
A synergistic effect between antigen receptors and TLRs
has been proposed to drive autoimmune responses by
activating self-reactive lymphocytes in the presence of
endogenous nucleic acids (Deane and Bolland, 2006;
Marshak-Rothstein and Rifkin, 2007). This theory stems
from the observation that B cells with DNA or RNA speci-
ficities are activated by nucleic acids in vitro (Fields et al.,
2006; Krieg et al., 1995; Lau et al., 2005; Leadbetter et al.,
2002; Viglianti et al., 2003). Genetically, it has been shown.
Immunity
Augmented TLR7 Expression Promotes AutoimmunityFigure 5. TLR7 Overexpression Produces a Highly Inflammatory Environment
(A) Dendritic cell expansion observed in peripheral blood (PB) and spleens (Spl) of TLR7.Tg.1 mice, as compared to B6 splenocytes by measuring
CD11c versus either CD11b or B220. Numbers in quadrants indicate percentages of total cells. Data are representative of three independent exper-
iments.
(B) Expression of costimulatory molecules in B6 and TLR7.Tg.1 dendritic cells. CD11c+ gated cells were stained with antibodies for IA-b (top) or CD80
(bottom). Overlays of TLR7.Tg.1 (red) and B6 (blue) littermates are shown, with numbers indicating MFI values. Data are representative of three
independent experiments.
(C) Assessment of inflammatory cytokines in serum from B6 and TLR7.Tg.1 mice. Sera from B6 (blue) or TLR.7.Tg.1 (red) mice were measured for
amounts of TNF-a, MCP-1, IL-6, IL-10, and IL-12. Values are shown as means ± SD from four independent pairs of mice, and statistically significant
values (p < 0.05) are marked by an asterisk while nonsignificant values (p > 0.05) are shown as n.s.
(D) Expression of interferon-signature genes in B6 and TLR7.Tg.1 dendritic cells. Quantitative PCR analysis ofmolecules related to interferon signaling
shows elevated levels of IRF5 and SOCS1, while IRF4 and IRG1 were not statistically different. Asterisk represents p < 0.05. Data were obtained from
four pairs of B6 and TLR7.Tg.1 mice that were 3–5 months of age.that deletion of TLR9 reduces the amount of DNA-related
antibodies in serum of lupus-prone mice, but how this
correlates with the inflammatory pathology is still unclear
(Christensen et al., 2005, 2006; Ehlers et al., 2006; Wu
and Peng, 2006). Knockout mouse studies have also
shown that deletion of Tlr7 is protective from anti-RNA B
cell responses (Berland et al., 2006; Christensen et al.,
2006). Although these studies reveal that TLR function is
necessary to develop certain B cell autoreactivities, they
do not address the precise role of TLR dysfunction in the
spontaneous onset of disease or in the inflammatory pa-
thology associated with autoimmune disorders. The Yaa
modifier, suggested to be caused by a duplication of the
Tlr7 gene (Pisitkun et al., 2006), provides the best example
of TLR dysregulation leading to autoreactivity and inflam-
matory pathology. Data presented in this manuscript
show that an increase in Tlr7 gene dosage can potentiate
systemic autoimmunity, because the phenotype of the
Yaa mouse was completely restored through loweringImTlr7 gene dosage. The 16 other duplicated genes were
thus not required to produce the accelerated autoimmu-
nity. Further, it was even more intriguing to find that, at
above a 2-fold overexpression, production of RNA auto-
antibodies and inflammatory cytokines could be observed
in a mouse that lacked any genetic lesions such as a null
allele of Fcgr2b. Thus, while TLR7 has been described
as a modifier of systemic autoimmunity, the present
work underscores the fact that dysregulation of TLR7 on
its own can break tolerance. Whether this will be true of
other genetic backgrounds such as BALB/c, which has
shown resistance to developing autoimmunity in other
instances, or even in human subjects, remains to be seen.
Future studies exploring cellular interactions in TLR7.Tg
mice may clarify the way that increased Tlr7 gene dosage
serves to intensify the severity of autoimmunity on a cellu-
lar level. We observe that multiple insertions of the Tlr7-
containing BAC clone results in augmented expression
of TLR7 in the same cell types (B cells and DCs) as whatmunity 27, 801–810, November 2007 ª2007 Elsevier Inc. 807
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Augmented TLR7 Expression Promotes AutoimmunityFigure 6. TLR7 Overexpression and Anemic Disease
(A) Measurement of WBCs, RBCs, hemoglobin, and hematocrit in the blood moribund (>3-month-old) TLR7.Tg.1 mice (red) versus B6 littermates
(blue). Data are shown as mean ± SD from four independent pairs of mice.
(B) Platelet counts in blood from moribund TLR7.Tg.1 mice (red) versus B6 littermates (blue). Data are shown as mean ± SD, from four independent
pairs of mice.
(C) Histological analysis of spleens from B6 or moribund TLR7.Tg.1 mice shows normal white pulp (WP) architecture in B6 mouse, with depletion of
WP in TLR7.Tg.1 mice, and white pulp focal histiocytosis (FH). Data are representative of four independent experiments.
(D) Flow cytometric analysis of spleens from B6 or moribund TLR7.Tg.1 mice shows an abundance of Ter-119+ erythroblasts, lymphoid depletion (as
judged by the decrease in CD4+, CD8+, and B220+ cells), and expansion of dendritic cells and myeloid cells. Data are representative of four indepen-
dent experiments.is detected for the endogenous gene (Bekeredjian-Ding
et al., 2005; Lund et al., 2004; Pisitkun et al., 2006). The
preference for anti-RNA specificities and the spontaneous
activation of lymphocytes observed in these transgenic
mice is most likely due to increased expression of TLR7
in B cells, because this phenotype was shown to be B
cell intrinsic in the Yaa mouse (Pisitkun et al., 2006). Over-
expression of TLR7 also leads to severe expansion of the
CD11c+ population, a cell type that is very restricted in
numbers when it develops in healthy conditions (Liu
et al., 2007; Steinman et al., 2005). Whether this dysregu-
lated expansion of DCs occurs as a result of increased
expression of TLR7 in DCs with consequent hyperactivity
of these cells or whether it happens in response to a highly
inflammatory environment is still undetermined.
Understanding which endogenous ligands serve to
activate these receptors and promote autoimmunity will
clarify how altered gene dosage has such a strong effect
on the maintenance of tolerance. Recent studies on
TLR9 indicate that binding a specific stimulatory ligand808 Immunity 27, 801–810, November 2007 ª2007 Elsevier Incis essential for a conformational change in the TLR, which
leads to activation of the NF-kB signalosome (Latz et al.,
2007). If this is true of TLR7, we can rule out that overex-
pression leads to constitutive activation in the absence
of ligand. Is affinity for host RNA low in a tolerant host
with normal amounts of TLR7 such that increased expres-
sion crosses a threshold of sensitivity where autoimmunity
results? The production of better reagents will allow these
sorts of questions to be addressed in the future.
Studies shown here on TLR7.Tg mice with the highest
expression revealed the importance of restricting TLR
activity to avoid the development of an extreme inflamma-
tory conditionwhere DC expansion dominates, resulting in
lymphoid atrophy, anemia, and other pathologies associ-
ated with autoimmunity. Finding elevated expression of
IRF5 and SOCS1 was particularly notable, because the
interferon signature has been argued to be an important
indicator of the severity of lupus, particularly in the case
of IRF5 (Graham et al., 2006; Pascual et al., 2006). Be-
cause interferon alpha itself serves to upregulate TLR7.
Immunity
Augmented TLR7 Expression Promotes Autoimmunityexpression, our model mirrors what may happen at the
RNA level when an interferon signature is developed (Be-
keredjian-Ding et al., 2005; Pascual et al., 2006). Thus,
TLR7-overexpressing transgenic mice provide not only
evidence for a role of TLRs in the onset of autoimmunity,
but also a useful and highly simplified genetic system to
study the development of severe autoimmune disease




Mice lacking TLR7 and FcgRIIB, and the Yaa strain of mice have
already been described (Lund et al., 2004; Murphy and Roths, 1979;
Takai et al., 1996). They were maintained on a C57BL/6 background
for at least 10 generations. Transgenic mice overexpressing TLR7
(TLR7.Tg) mice were generating by recombineering BAC clone RP23-
139P21 with the Quick and Easy BAC modification kit (Open Biosys-
tems). DNA was injected into C57BL/6-derived zygotes, and positive
founders were identified by Southern blots for a neomycin resistance
cassette. All animals were housed and studied under approved institu-
tional ACUC guidelines.
Cellular Analysis
Collagenase D-treated splenocyte suspensions were stained with an-
tibodies to the followingmolecules: B220, CD4, CD8a, CD11c, CD11b,
CD21, CD23, CD40, CD69, CD138, IA-b, and Ter-119 (BD Biosci-
ences). These cells were analyzed on a FACS Calibur flow cytometry
machine and were later analyzed further with FlowJo (Tree Star, Ash-
land, OR). Follicular B cells were purified with an AutoMACS machine
(Miltenyi) by negative selection, via biotinylated antibodies to CD11c,
CD43, and CD9 (BD Biosciences) and anti-Biotin magnetic beads (Mil-
tenyi). Imiquimod, CpG ODN1826, and control ODN186 (Invivogen)
were added to evaluate proliferation in splenocytes in 3H-thymidine
incorporation assays, which were performed as described (Pisitkun
et al., 2006).
Pathology
Necropsies were performed on selected mice. Tissues were fixed with
neutral buffered formalin and embedded in paraffin, and sections were
stained with hematoxylin and eosin. Frozen or paraffin-embedded
sections of spleen, lymph nodes, and kidneys were analyzed with a
variety of antibodies, including H&E, anti-MOMA-1 FITC, anti-B220-
APC. Kappa Light Chains (Catalog # A0191 from Dako Corporation,
Carpinteria, CA) were used on paraffin-embedded sections, at a dilu-
tion of 1:1000. The Kappa Light Chain stain utilized Pro-K, catalog #
S3020, enzyme digestion from Dako Corporation. They were then
stained with the Anti-Rabbit envision + polymer system from Dako
Corporation. All slides used the Cardassian DAB chromogen counter-
stained with the modified Harris hematoxylin from Biocare Medical
(Concord, CA).
Serological Analysis
Serum was tested for autoantibody production by a standard autoan-
tibody test with Hep-2 cells fixed on slides (Bion). Sera were diluted
1:200, and after two washes, a goat anti-mouse IgG secondary anti-
body (Sigma) was used to identify autoreactive sera. Sera were also
used for an ELISA to detect RNA autoantibodies with a kit from Immco
Diagnostics (Buffalo, NY). Additionally, sera were analyzed for cyto-
kines with the BD CBA Inflammation kit.
Hematological Analysis
Whole blood in EDTA was analyzed with a Cell Dyn 3500 System from
Abbott Laboratories (Abbott Park, IL).ImReal-Time Quantitative PCR
Quantitative PCR on genomic DNA and cDNA were used to measure
levels of the following genes: TLR7 and b-Actin, as described previ-
ously (Pisitkun et al., 2006). For measuring levels of IRF-4, IRF-5,
and SOCS1, a Sybr green based assay was performed, with primers
for IRF-4, IRF-5, SOCS1, and b-Actin, as described previously (Honma
et al., 2005; Takaoka et al., 2005).
Statistical Analysis
To determine statistical significance, p values were calculated by
a paired Student’s t test. Values less than 0.05 were considered signif-
icant.
Supplemental Data
Two figures and two tables are available at http://www.immunity.com/
cgi/content/full/27/5/801/DC1/.
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